Related Experiment Video
Updated: May 26, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
Published on: November 4, 2011
FDA preemption of drug and device labeling: who should decide what goes on a drug label?
1Boulware & Valoir, Houston, USA. tvaloir@boulwarevaloir.com
Abstract:
The Supreme Court decided an issue that is critical to consumer health and safety last year. In April 2009, the Supreme Court held that extensive FDA regulation of drugs did not preempt a state law claim that an additional warning on the label was necessary to make the drug reasonably safe for use. Thus, states--and even courts and juries--are now free to cast their vote on what a drug label should say. This is in direct contrast to medical devices, where the federal statute regulating medical devices expressly provides that state regulations are preempted. This Article discusses basic preemption principles and drugs, and explores the policy ramifications of pro- and anti-preemption policy in the healthcare industry.
More Related Videos
Related Concept Videos
Drug Regulation
FDA Approved Drugs: Changes to Approved Drugs
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Nomenclature
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Biopharmaceutical Factors Influencing Drug Product Design: Overview

